Compare National Beverage Corp. (FIZZ) vs Teladoc Health Inc (TDOC) Price & Performance

FIZZ trades at $32.09, up 3.78% on the day, but the stock faces bearish technical signals and mixed earnings results, with three of the last four quarters missing EPS estimates. The company maintains solid profitability with a 15.56% net income margin and a 34.03% ROE, while a recent special dividend of $3.25 per share reflects shareholder returns. However, revenue has stagnated around $1.2 billion annually, and analyst sentiment is cautious, with 50% of coverage recommending Sell.

The outlook for FIZZ is clouded by stalled growth and competitive pressures, particularly for its LaCroix brand. While valuation multiples like a P/E of 15.73 appear reasonable, the lack of revenue catalysts and bearish technical trends suggest limited near-term upside. Key risks include declining volumes and consumer weakness, requiring investors to weigh dividend returns against fundamental headwinds.

TDOC trades at $9.56, up 3.13% with bullish technical signals from moving averages. The company reported mixed Q1 2026 earnings, missing expectations with a -$0.36 EPS, but maintains strong revenue of $2.53B and a gross margin of 69.29%. Recent partnership expansions with Walmart highlight growth initiatives, though net losses persist at -$200.32M. Analyst consensus is mixed with 35.71% buy ratings but a price target below current levels at $8.75.

The outlook remains cautious due to ongoing net losses and negative cash flow trends, with net cash flow at -$517.24M in 2025. Key risks include competitive pressures and execution challenges, but cost-cutting and market expansion could support recovery. Investors should weigh the low P/S ratio of 0.69 against profitability concerns.